Plaquenil

Generic name: Hydroxychloroquine

Usage of Plaquenil

Plaquenil is used to treat or prevent malaria, a disease caused by parasites that enter the body through the bite of a mosquito. Hydroxychloroquine is not effective against all strains of malaria, or against malaria in areas where the infection has been resistant to a similar drug called chloroquine.

Plaquenil is also used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus.

Plaquenil side effects

Get emergency medical help if you have signs of an allergic reaction to Plaquenil (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Also seek emergency medical attention if you have symptoms of a serious heart problem: fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out).

Call your doctor at once if you have:

a seizure;

yellowing of your eyes;

ringing in your ears, trouble hearing;

unusual mood changes;

severe muscle weakness, loss of coordination, underactive reflexes;

any sudden changes in mood or behavior, or thoughts about suicide;

low blood cell counts - fever, chills, tiredness, sore throat, mouth sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath;

low blood sugar - headache, hunger, sweating, irritability, dizziness, fast heart rate, and feeling anxious or shaky; or

a serious drug reaction that can affect many parts of your body - skin rash, fever, swollen glands, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes.

Taking Plaquenil long-term or at high doses may cause irreversible damage to the retina of your eye. Stop taking Plaquenil and tell your doctor if you have:

blurred vision, trouble focusing, trouble reading;

distorted vision, blind spots;

changes in your color vision;

hazy or cloudy vision;

seeing light flashes or streaks, seeing halos around lights; or

increased sensitivity to light.

Common Plaquenil side effects may include:

headache, dizziness;

nausea, vomiting, stomach pain;

loss of appetite, weight loss;

feeling nervous or irritable;

skin rash or itching; or

hair loss.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Plaquenil

You should not use Plaquenil if you are allergic to hydroxychloroquine or chloroquine.

High doses or long-term use of Plaquenil may cause irreversible damage to your retina (the membrane layer inside your eye that helps produce vision). This could progress to permanent vision problems. The risk of retinal damage is higher in people with pre-existing eye problems, kidney disease, or people who also take tamoxifen.

To make sure Plaquenil is safe for you, tell your doctor if you have ever had:

vision changes or damage to your retina caused by an anti-malaria medication;

heart disease, heart rhythm disorder (such as long QT syndrome);

diabetes;

a stomach disorder;

an allergy to quinine;

liver or kidney disease;

psoriasis;

alcoholism;

porphyria (a genetic enzyme disorder that causes symptoms affecting the skin or nervous system); or

a genetic enzyme deficiency called glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Tell your doctor if you are pregnant or plan to become pregnant. Malaria is more likely to cause serious illness or death in a pregnant woman. Having malaria during pregnancy may also increase the risk of miscarriage, stillbirth, premature delivery, and low birth weight.

If you are pregnant, your name may be listed on a pregnancy registry to track the effects of hydroxychloroquine on the baby.

It is not known whether hydroxychloroquine will harm an unborn baby. If you are pregnant, ask your doctor about the risks of traveling to areas where malaria is common (such as Africa, South America, and Southern Asia).

It may not be safe to breastfeed while using Plaquenil. Ask your doctor about any risk.

Plaquenil is not approved for treating lupus or rheumatoid arthritis in anyone younger than 18 years old.

How to use Plaquenil

Usual Adult Dose of Plaquenil for Malaria Prophylaxis:

400 mg salt (310 mg base) orally once a week Weight-based dosing: 6.5 mg/kg salt (5 mg/kg base) orally once a week -Maximum dose: 400 mg salt (310 mg base)/dose Comments: -This drug should be administered on the same day of each week. -Suppressive therapy should begin 2 weeks prior to exposure and should continue for 4 weeks after leaving the endemic area. Use: For the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported US CDC Recommendations: 310 mg base (400 mg salt) orally once a week Comments: -An alternative to chloroquine for prophylaxis only in areas with chloroquine-sensitive malaria -Prophylaxis should start 1 to 2 weeks before travel to malarious areas; should continue weekly (same day each week) while in malarious areas and for 4 weeks after leaving such areas -If malaria develops while using this drug for chemoprophylaxis, it should not be used as part of the treatment regimen. -Current guidelines should be consulted for additional information.

Usual Adult Dose of Plaquenil for Malaria:

800 mg salt (620 mg base) orally as an initial dose, followed by 400 mg salt (310 mg base) at 6, 24, and 48 hours after the initial dose Total dose: 2000 mg salt (1550 mg base) Weight-based dosing: -First dose: 13 mg/kg salt (10 mg/kg base) orally -Second dose (6 hours after first dose): 6.5 mg/kg salt (5 mg/kg base) orally -Third dose (24 hours after first dose): 6.5 mg/kg salt (5 mg/kg base) orally -Fourth dose (48 hours after first dose): 6.5 mg/kg salt (5 mg/kg base) orally Maximum Dose: -First dose: 800 mg salt (620 mg base)/dose -Second, third, and fourth dose: 400 mg salt (310 mg base)/dose Comments: -Concomitant therapy with an 8-aminoquinoline compound is necessary for radical cure of Plasmodium vivax and P ovale infections. Use: For the treatment of uncomplicated malaria due to P falciparum, P malariae, P ovale, and P vivax US CDC Recommendations: 620 mg base (800 mg salt) orally at once, followed by 310 mg base (400 mg salt) orally at 6, 24, and 48 hours Total dose: 1550 mg base (2000 mg salt) Comments: -Recommended for uncomplicated malaria (P falciparum or species not identified) in regions with chloroquine sensitivity -Recommended for uncomplicated malaria (P malariae, P knowlesi, P vivax [unless chloroquine-resistant P vivax suspected], or P ovale) in all regions; if treating P vivax or P ovale infections, concomitant treatment with primaquine (after quantitative testing to rule out glucose-6-phosphate dehydrogenase [G6PD] deficiency) is recommended. -Recommended for uncomplicated malaria treatment for pregnant women in regions with chloroquine sensitivity -Current guidelines should be consulted for additional information.

Usual Adult Dose of Plaquenil for Systemic Lupus Erythematosus:

200 to 400 mg salt (155 to 310 mg base)/day orally divided in 1 or 2 doses Comments: -Doses above 400 mg/day are not recommended. -Higher incidence of retinopathy reported when this maintenance dose is exceeded. Uses: For the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus

Usual Adult Dose of Plaquenil or Rheumatoid Arthritis:

Initial dose: 400 to 600 mg salt (310 to 465 mg base)/day orally divided in 1 or 2 doses Maintenance dose: 200 to 400 mg salt (155 to 310 mg base)/day orally divided in 1 or 2 doses Maximum dose: 600 mg salt (465 mg base)/day or 6.5 mg/kg salt (5 mg/kg base)/day, whichever is lower Comments: -The action of this drug is cumulative and may require weeks to months to achieve the maximum therapeutic effect. -When a good response is obtained, the initial dose may be reduced by 50% and continued at a maintenance dose. -Higher incidence of retinopathy reported when this maintenance dose is exceeded; 600 mg salt (465 mg base) or 6.5 mg/kg salt (5 mg/kg base), whichever is lower, should not be exceed per day. -Corticosteroids and salicylates may be used with this drug, and they can generally be decreased gradually in dosage or eliminated after a maintenance dose of this drug has been achieved. Use: For the treatment of acute and chronic rheumatoid arthritis

Usual Pediatric Dose of Plaquenil for Malaria Prophylaxis:

6.5 mg/kg salt (5 mg/kg base) orally once a week Maximum dose: 400 mg salt (310 mg base)/dose Comments: -This drug should be administered on the same day of each week. -Suppressive therapy should begin 2 weeks prior to exposure and should continue for 4 weeks after leaving the endemic area. Use: For the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported US CDC Recommendations: 5 mg/kg base (6.5 mg/kg salt) orally once a week Maximum dose: 310 mg base (400 mg salt)/dose Comments: -An alternative to chloroquine for prophylaxis only in areas with chloroquine-sensitive malaria -Prophylaxis should start 1 to 2 weeks before travel to malarious areas; should continue weekly (same day each week) while in malarious areas and for 4 weeks after leaving such areas -If malaria develops while using this drug for chemoprophylaxis, it should not be used as part of the treatment regimen. -Current guidelines should be consulted for additional information.

Usual Pediatric Dose of Plaquenil for Malaria:

First dose: 13 mg/kg salt (10 mg/kg base) orally Second dose (6 hours after first dose): 6.5 mg/kg salt (5 mg/kg base) orally Third dose (24 hours after first dose): 6.5 mg/kg salt (5 mg/kg base) orally Fourth dose (48 hours after first dose): 6.5 mg/kg salt (5 mg/kg base) orally Maximum Dose: -First dose: 800 mg salt (620 mg base)/dose -Second, third, and fourth dose: 400 mg salt (310 mg base)/dose Comments: -Concomitant therapy with an 8-aminoquinoline compound is necessary for radical cure of P vivax and P ovale infections. Use: For the treatment of uncomplicated malaria due to P falciparum, P malariae, P ovale, and P vivax US CDC Recommendations: 10 mg/kg base orally at once, followed by 5 mg/kg base orally at 6, 24, and 48 hours Total dose: 25 mg/kg base Comments: -Pediatric dose should never exceed adult dose. -Recommended for uncomplicated malaria (P falciparum or species not identified) in regions with chloroquine sensitivity -Recommended for uncomplicated malaria (P malariae, P knowlesi, P vivax [unless chloroquine-resistant P vivax suspected], or P ovale) in all regions; if treating P vivax or P ovale infections, concomitant treatment with primaquine (after quantitative testing to rule out G6PD deficiency) is recommended. -Current guidelines should be consulted for additional information.

Warnings

Plaquenil can cause dangerous effects on your heart, especially if you also use certain other medicines including the antibiotic azithromycin (Z-Pak). Seek emergency medical attention if you have fast or pounding heartbeats and sudden dizziness (like you might pass out).

Taking Plaquenil long-term or at high doses may cause irreversible damage to the retina of your eye that could progress to permanent vision problems.

Stop taking Plaquenil and call your doctor at once if you have blurred vision, trouble focusing, distorted vision, blind spots, trouble reading, changes in your color vision, increased sensitivity to light.

What other drugs will affect Plaquenil

Plaquenil can cause a serious heart problem. Your risk may be higher if you also use certain other medicines for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV.

Tell your doctor about all your other medicines, especially:

cimetidine;

cyclosporine;

methotrexate;

rifampicin;

praziquantel;

ampicillin;

digoxin;

tamoxifen; or

heart rhythm medicine;

This list is not complete. other drugs may interact with hydroxychloroquine, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.